<DOC>
	<DOCNO>NCT01240811</DOCNO>
	<brief_summary>This pilot study perform investigate influence start contraception IUD local immune cell population feature , particular focus cell cell-surface feature important HIV transmission ( CD4 cell CCR5 cell receptor ) . Based result large epidemiologic study seem consistent find slightly increase HIV acquisition woman use hormonal contraception . It clear due biological phenomenon relate difference sexual behaviors/risks woman hormonal contraceptive . The study hypothesis CD4 cell CCR5 HIV-tropic receptor density increase within upper low genital tract woman 2 month placement progestin-containing intrauterine device contraception compare woman use hormonal contraception .</brief_summary>
	<brief_title>Study Immune Cell Changes Genital Tract 2 Months After Initiation IUD Contraception</brief_title>
	<detailed_description />
	<mesh_term>Copper</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<criteria>1 . Nonpregnant , healthy female seek IUD contraception 2 . Age 1840 year , inclusive time enrollment 3 . History regular menstrual cycle define occur every 2135 day use hormones variation typical cycle length 5 day 4 . Willing able sign inform consent comply study protocol Inclusion criterion healthy control subject : 1 . Nonpregnant , healthy female 2 . Age 1840 year , inclusive time enrollment 3 . History regular menstrual cycle define occur every 2135 day use hormones variation typical cycle length 5 day 4 . Willing able sign inform consent comply study protocol 5 . Prior surgical sterilization heterosexually abstinent 1 . Use hormonal intrauterine contraceptive method within past two month 2 . Use DMPA within past 10 month 3 . Any follow within past two month : Pregnancy breastfeed Surgery/biopsy vulva , vagina , cervix History STI New sexual partner 4 . Evidence vaginal/pelvic infection screen Abnormal wet mount ( see description ) Pelvic exam finding clinically consistent infection Positive screen Gc , Ct , HIV ( exclude post randomization ) 5 . Active HSV/ulcerative disease genital tract perineum 6 . History immunosuppression ( diabetes , HIV , chronic steroid use ) 7 . Use vaginal product ( N9 , microbicide , douche , antifungal , steroid , hormone ) within past 30 day 8 . Use systemic vaginal steroid antibiotic within past 30 day 9 . Vaginal anal intercourse within 1 week sample collection 10 . Heterosexual vaginal intercourse since last menses without condom use 11 . History hysterectomy 12 . History malignancy uterus cervix 13 . Uterine anomaly ( bicornuate uterus , uterine septum , uterine didelphys ) 14 . Allergy copper and/or intolerance levonorgestrel</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>intrauterine device</keyword>
	<keyword>IUD</keyword>
	<keyword>levonorgestrel</keyword>
	<keyword>copper</keyword>
	<keyword>CD4</keyword>
	<keyword>CCR5</keyword>
	<keyword>microflora</keyword>
</DOC>